BioCentury | Apr 10, 2018
Distillery Therapeutics

Autoimmune disease

...in Phase I testing for melanoma, MM, non-small cell lung cancer (NSCLC) and solid tumors. Karus Therapeutics Ltd....
BioCentury | Oct 24, 2017
Distillery Therapeutics

Neurology

...Regenacy Pharmaceuticals LLC also have ricolinostat in preclinical testing to treat chemotherapy-induced peripheral neuropathy (CIPN). Karus Therapeutics Ltd....
BioCentury | Nov 3, 2016
Translation in Brief

One plus one equals four

...broader combination modalities than have been possible in the past with pan inhibitors.” Stephen Shuttleworth, Karus...
...conducive to broader combination modalities than have been possible in the past with pan inhibitors.” Karus...
...phosphatase and tensin homolog deleted on chromosome ten ( PTEN ; MMAC1 ; TEP1 ). Karus...
BioCentury | Oct 17, 2016
Clinical News

KA2237: Phase I started

...for an expansion cohort in the second part, which is slated to begin next year. Karus Therapeutics Ltd....
BioCentury | Mar 23, 2015
Finance

Expanding IP

...diagnostic investments, including genome sequencing play Oxford Nanopore Technologies Ltd. , autoimmune and cancer company Karus Therapeutics Ltd....
BioCentury | Oct 27, 2014
Company News

Karus management update

Karus Therapeutics Ltd. , Chilworth, U.K. Business: Autoimmune, Caner Hired: Peter Finan as head of biology, formerly VP and global head of respiratory disease at Novartis AG ; and Simon Roitt as head of clinical development,...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...Inc. , Amgen Inc. , AstraZeneca plc , Atlas Venture, Biogen Idec Inc. , GlaxoSmithKline, Karus Therapeutics Ltd....
...Now there are at least 18 known HDACs in humans, and companies including Acetylon and Karus...
...been able to identify that exquisite isoform specificity that correlates with the better safety profile." Karus...
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Neurology

...Inc. have the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd....
BioCentury | Nov 18, 2013
Company News

Karus management update

Karus Therapeutics Ltd. , Chilworth, U.K. Business: Autoimmune, Cancer Hired: Penelope Ward as CMO WIR Staff autoimmune cancer...
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...Inc. have ACY-1215, an HDAC6 inhibitor, in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd....
Items per page:
1 - 10 of 26
BioCentury | Apr 10, 2018
Distillery Therapeutics

Autoimmune disease

...in Phase I testing for melanoma, MM, non-small cell lung cancer (NSCLC) and solid tumors. Karus Therapeutics Ltd....
BioCentury | Oct 24, 2017
Distillery Therapeutics

Neurology

...Regenacy Pharmaceuticals LLC also have ricolinostat in preclinical testing to treat chemotherapy-induced peripheral neuropathy (CIPN). Karus Therapeutics Ltd....
BioCentury | Nov 3, 2016
Translation in Brief

One plus one equals four

...broader combination modalities than have been possible in the past with pan inhibitors.” Stephen Shuttleworth, Karus...
...conducive to broader combination modalities than have been possible in the past with pan inhibitors.” Karus...
...phosphatase and tensin homolog deleted on chromosome ten ( PTEN ; MMAC1 ; TEP1 ). Karus...
BioCentury | Oct 17, 2016
Clinical News

KA2237: Phase I started

...for an expansion cohort in the second part, which is slated to begin next year. Karus Therapeutics Ltd....
BioCentury | Mar 23, 2015
Finance

Expanding IP

...diagnostic investments, including genome sequencing play Oxford Nanopore Technologies Ltd. , autoimmune and cancer company Karus Therapeutics Ltd....
BioCentury | Oct 27, 2014
Company News

Karus management update

Karus Therapeutics Ltd. , Chilworth, U.K. Business: Autoimmune, Caner Hired: Peter Finan as head of biology, formerly VP and global head of respiratory disease at Novartis AG ; and Simon Roitt as head of clinical development,...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...Inc. , Amgen Inc. , AstraZeneca plc , Atlas Venture, Biogen Idec Inc. , GlaxoSmithKline, Karus Therapeutics Ltd....
...Now there are at least 18 known HDACs in humans, and companies including Acetylon and Karus...
...been able to identify that exquisite isoform specificity that correlates with the better safety profile." Karus...
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Neurology

...Inc. have the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd....
BioCentury | Nov 18, 2013
Company News

Karus management update

Karus Therapeutics Ltd. , Chilworth, U.K. Business: Autoimmune, Cancer Hired: Penelope Ward as CMO WIR Staff autoimmune cancer...
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...Inc. have ACY-1215, an HDAC6 inhibitor, in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd....
Items per page:
1 - 10 of 26